A urinary DNA methylation test demonstrated high sensitivity and specificity for detecting high-grade or invasive bladder cancer, outperforming both nuclear matrix protein 22 (NMP22) and urine ...

A urinary DNA methylation test displayed superior sensitivity for detecting high-grade or invasive bladder cancer, compared with the nuclear matrix protein 22 (NMP22) test or urine cytology test.

All patients provided a voided urine sample for cytologic and NMP22 analyses before undergoing cystoscopy. Patients with suspicious cystoscopy or cytology results were further investigated with ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This abstract does not include a full text component.

Nuclear matrix protein-22 (NMP22) is approved for clinical use by the FDA. However, the UroScreen study—the largest prospective validation study for early detection of bladder cancer—has ...

Findings indicate that the test demonstrated 89.2% sensitivity and 87.8% specificity for detecting high-grade or invasive bladder cancer, surpassing the nuclear matrix protein 22 (NMP22 ...

The company's leading product, the NMP22(R) BladderChek(R) Test is a point-of-care test cleared by the FDA for both the diagnosis and monitoring of bladder cancer. Inverness, a leading ...

Impact of clinicopathological features on survival in patients treated with immune-based combinations for metastatic urothelial carcinoma: A meta-analysis of randomized clinical trials. This is an ...

The trial team found that the Mcm5 urine test was as reliable and accurate as the standard NMP22 urine test for diagnosing bladder cancer. This trial recruited 1,677 people. Of the 1,564 urine samples ...